Communicating with our patients is important to us, which is why we launched a new website focused on readily available content for the patient.
New guidance has been issued for the use of the Oxford AstraZeneca Covid-19 vaccine.
This follows further reviews by the independent regulator, the MHRA, and the Commission for Human Medicines, of a very small number of people in the UK who have developed a rare blood-clotting condition since having the Oxford AstraZeneca Covid-19 vaccine.
The MHRA and Joint Committee for Vaccinations and Immunisations have emphasised that the risk of this condition is extremely small and that the benefits of the vaccine outweigh the risks for the vast majority of people. They have recommended that:
Please see the leaflet below that has been produced by Public Health England and the NHS to answer any questions you may have
Leaflet on COVID-19 vaccination and blood clotting